KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Debt (2019 - 2025)

Royalty Pharma's Non-Current Debt history spans 7 years, with the latest figure at $8.6 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 29.57% year-over-year to $8.6 billion; the TTM value through Dec 2025 reached $8.6 billion, up 29.57%, while the annual FY2025 figure was $8.6 billion, 29.57% up from the prior year.
  • Non-Current Debt for Q4 2025 was $8.6 billion at Royalty Pharma, roughly flat from $8.6 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $8.6 billion in Q4 2025 and bottomed at $5.8 billion in Q1 2021.
  • The 5-year median for Non-Current Debt is $6.6 billion (2024), against an average of $6.7 billion.
  • The largest annual shift saw Non-Current Debt fell 13.78% in 2023 before it rose 29.58% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $7.1 billion in 2021, then decreased by 13.77% to $6.1 billion in 2022, then grew by 0.27% to $6.1 billion in 2023, then rose by 7.81% to $6.6 billion in 2024, then increased by 29.57% to $8.6 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Non-Current Debt are $8.6 billion (Q4 2025), $8.6 billion (Q3 2025), and $7.0 billion (Q2 2025).